4
Changes in Ownership
NEKTAR THERAPEUTICS Filed Acc 0001209191-23-030448
Chief R&D Officer sold 9,791 shares at $0.72 ($7,050)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Zalevsky Jonathan Chief R&D Officer | 2023-05-16 | Sale | −9,791 | $0.72 | $7,050 | 293,388 | D |
| Open-market sales · 9,791 sh · avg $0.72 · $7,050 | |||||||
Loading xslF345X04/doc4.xml…